"The comparisons to Hyperfine are fruitless. They're different products with different applications, both within a similar market sector"
I don't understand your logic here. My research tells me that both Hyperfine Swoop and EMV's Gen 1 device are addressing the in-hospital point of care brain imaging market (for stroke, traumatic brain injury etc). Just like both EMV, with its Gen 2 device, and MX1 are addressing the pre-hospital point of care brain imaging market.
Being aware of what Hyperfine is doing - and what MX1 is doing - is just a normal part of the SWOT mindset. Not a great idea to just focus on the strengths and opportunities.
As I have already posted a couple of times, I am not worried about Hyperfine as I think we will be highly competitive and Hyperfine is doing a lot for us in raising market awareness of point of care imaging. But we need, in my opinion, to be aware of their moves and market strategies.
EMvision Research Notes, page-1719
-
- There are more pages in this discussion • 1,002 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.00 |
Change
0.000(0.00%) |
Mkt cap ! $171.0M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.06 | $2.00 | $59.88K | 29.81K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15000 | $1.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 4830 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| EMV (ASX) Chart |